 |
|
|
| |
The outcome of 24 vs. 48 weeks of peginterferon alfa-2a (40KD) plus ribavirin on sustained virologic response rates in patients infected with genotype 2 or 3 hepatitis C virus who do not achieve a rapid viral response: the N-CORE study
|
| |
| |
Reported by Jules Levin
AASLD 2012 Nov 9-13 Boston
Hugo Cheinquer,*Mitchell L. Shiffman, Stefan Zeuzem, Christoph Berg, Thomas Berg, Cláudio de Figueiredo- Mendes, Gregory Dore, Maria Lucia Ferraz, Maria Cassia Mendes-Correa, Maria Patelli-Lima, Edison Parise, Alma Perez-Rios, Tania Reuter, Arun Sanyal, Stephen Shafran, Marc Hohmann, Fernando Tatsch
*Hospital de Clínicas de Porto Alegre, Brazil
|
| |
|
|
|
|
|
